DruSO-CU

This international project aims to calculate the drug survival of omalizumab in a large multicenter daily practice cohort of patients with CU treated in UCARE centers, and identify determinants of drug survival in this overall international population differentiated by reason of discontinuation.

Contact: H.Rockmann@umcutrecht.nl

News

TempTest available again – special price for all UCAREs

Courage&Khazaka has announced that TempTest® is available again

Read more

Insights into

5th GA²LEN Global Urticaria Forum (GUF 2020) and 6th Consensus Conference on the Update and Revision of the international EAACI/GA²LEN/EuroGuiDerm/APAAACI Guideline for Urticaria

Read more

EAACI YouTube channel promoting the articles published in our journal

One of Allergy’s goals is to disseminate your research and expand the readership of your important data. As such, we have created a YouTube channel promoting the articles published in our journal.

Read more

Contact us

GA²LEN coordinating Office
c/o DGAKI
Robert-Koch-Platz 7
10115 Berlin, Germany

UCARE office
Laura Schwenner

info(at)ga2len-ucare.com